United Therapeutics (UTHR) Share-based Compensation Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Share-based Compensation Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -83.20% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -2.48% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 20.81% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 18.94% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 7.25% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -1.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 62.85% |
| Dec 31, 2025 | -15.57% |
| Sep 30, 2025 | 163.48% |
| Jun 30, 2025 | -16.74% |
| Mar 31, 2025 | 51.93% |
| Dec 31, 2024 | -15.47% |
| Sep 30, 2024 | 19.23% |
| Jun 30, 2024 | 19.53% |
| Mar 31, 2024 | -13.89% |
| Dec 31, 2023 | -43.84% |
| Sep 30, 2023 | 39.59% |
| Mar 31, 2023 | -24.04% |
| Dec 31, 2022 | 29.99% |
| Sep 30, 2022 | -26.46% |
| Jun 30, 2022 | -19.78% |
| Mar 31, 2022 | -39.64% |
| Dec 31, 2021 | 151.80% |
| Sep 30, 2021 | -37.00% |
| Jun 30, 2021 | -36.38% |
| Mar 31, 2021 | 33.82% |